# PHARMACY **BENEFACT**

Number 1057 • September 2022

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS®

## Product supply shortage addressed for the Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Sandoz Canada that the shortage for Sandoz Travoprost 0.004% Ophthalmic Solution (DIN 02413167) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 29, 2022**. The following grouping was removed from the Critical Supply Product List **August 31, 2022**.

#### TRAVOPROST

0.004% OPHTALMIC SC	0.004% OPHTALMIC SOLUTION							
00002413167	SANDOZ TRAVOPROST	SDZ	\$ 8.6280					
00002318008	TRAVATAN	PAL	\$ 11.6960					

Alberta Blue Cross has been advised by Accel Pharma Inc. that the shortage for Accel-Entecavir 0.5 mg Tablet (DIN 02479907) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 3, 2022**. The following grouping was removed from the Critical Supply Product List **September 2, 2022** 

#### **ENTECAVIR**

0.5 MG TABLET								
	00002479907	ACCEL-ENTECAVIR	ACP	\$ 4.4000				
	00002396955	APO-ENTECAVIR	APX	\$ 5.5000				
	00002448777	AURO-ENTECAVIR	AUR	\$ 5.5000				
	00002453797	ENTECAVIR	STR	\$ 5.5000				
	00002467232	JAMP-ENTECAVIR	JPC	\$ 5.5000				
	00002485907	MINT-ENTECAVIR	MPI	\$ 5.5000				
	00002430576	PMS-ENTECAVIR	PMS	\$ 5.5000				
	00002282224	BARACLUDE	BMS	\$ 22.6601				

continued next page





### PHARMACY BENEFACT

continued from previous page

Alberta Blue Cross has been advised by Accel Pharma Inc. that the shortage for Accel-Duloxetine 60 mg Delayed-Release Capsule (DIN 02522888) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 3, 2022**. The following grouping was removed from the Critical Supply Product List **September 2, 2022**.

#### DULOXETINE HYDROCHLORIDE

60 MG DELAYED-RELEASE CAPSULE									
00002522888	ACCEL-DULOXETINE	ACP	\$ 0.7327						
00002475316	AG-DULOXETINE	AGP	\$ 0.9769						
00002440431	APO-DULOXETINE	APX	\$ 0.9769						
00002436655	AURO-DULOXETINE	AUR	\$ 0.9769						
00002453649	DULOXETINE	SIV	\$ 0.9769						
00002490897	DULOXETINE	SNS	\$ 0.9769						
00002451921	JAMP-DULOXETINE	JPC	\$ 0.9769						
00002473216	M-DULOXETINE	MTR	\$ 0.9769						
00002446103	MAR-DULOXETINE	MAR	\$ 0.9769						
00002438992	MINT-DULOXETINE	MPI	\$ 0.9769						
00002482134	NRA-DULOXETINE	NRA	\$ 0.9769						
00002429454	PMS-DULOXETINE	PMS	\$ 0.9769						
00002439956	SANDOZ DULOXETINE	SDZ	\$ 0.9769						
00002456761	TEVA-DULOXETINE	TEV	\$ 0.9769						
00002301490	CYMBALTA	LIL	\$ 4.2351						

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area) 403-294-4041 (Calgary and area) 1-800-361-9632 (toll free) FAX 780-498-8406 (Edmonton and area) FAX 1-877-305-9911 (toll free)



Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php



\*\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. \*† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.1057 2022/09